When the Akreos MICSlens is coupled with the Stellaris MICS Vision Enhancement System, small incision surgeons can enjoy the universal advantages provided by the MICS Platform. The advantages include increased wound sealability, and a reduction in both endothelial cell loss and surgically-induced astigmatism.

Dr. John Hunkeler, Overland Park, Kansas City, was chosen to be among the first surgeons to implant the lens in the US. “This is what we’ve been waiting for… a crystal-clear acrylic lens with no yellow tint, vacuoles, or glistenings. I am yet to have any patient complain of edge glare or temporal darkness syndrome that has been reported with other acrylic IOLs. The four-point-fixation offers unparalleled centration. Besides all that, it delivers through a 1.8-mm incision. This is the perfect lens that my patients deserve” said Dr. Hunkeler.

On June 24, 2009 the Centers for Medicare and Medicaid Services (“CMS”) granted New Technology Intraocular Lens (“NTIOL”) designation to the Akreos MICS IOL for its spherical aberration reducing design. The NTIOL designation became effective April 30, 2009. NTIOL designation means the Medicare reimbursement to ambulatory surgery centers for cataract surgery will increase by $50 when surgery is performed with the Akreos MICS IOL.

Mike Judy, vice president of worldwide marketing for Bausch & Lomb Surgical stated, “We have strategically timed the launch of the Akreos MICS IOL in order to best support surgeons and their patients by providing our latest technological advancements in aspheric optics with NTIOL designation. By introducing an advanced technology lens with a designation that recognizes the high level of performance this lens provides, we continue the Bausch & Lomb tradition of delivering quality products and innovation that perfect vision and enhance life.”